<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506959</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0516</org_study_id>
    <secondary_id>NCI-2015-01308</secondary_id>
    <secondary_id>2014-0516</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02506959</nct_id>
  </id_info>
  <brief_title>Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma</brief_title>
  <official_title>Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well panobinostat, gemcitabine hydrochloride, busulfan, and&#xD;
      melphalan before stem cell transplant work in treating patients with multiple myeloma that&#xD;
      does not respond to treatment (refractory) or has returned (relapsed). Panobinostat may stop&#xD;
      the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving&#xD;
      high-dose chemotherapy, such as gemcitabine hydrochloride, busulfan, and melphalan, before a&#xD;
      peripheral blood stem cell transplant helps kill any cancer cells that are in the body and&#xD;
      helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to&#xD;
      grow. Previously collected stem cells are then returned to the patient to replace the&#xD;
      blood-forming cells that were destroyed by the chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the progression-free survival (PFS) in patients with refractory or relapsed&#xD;
      myeloma receiving panobinostat/gemcitabine hydrochloride (gemcitabine)/busulfan/melphalan&#xD;
      (panobinostat/Gem/Bu/Mel) with autologous stem-cell transplant, either as a first or a&#xD;
      salvage stem-cell transplant.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the complete response (CR) rate. II. To determine the overall survival (OS).&#xD;
      III. To determine the CR + very good partial remission (VGPR) rate. IV. To determine the&#xD;
      overall response rate (ORR). V. To determine minimal residual disease posttransplant,&#xD;
      measured by multiparametric flow cytometry (MFC).&#xD;
&#xD;
      VI. To describe the toxicity profile of panobinostat/Gem/Bu/Mel. VII. To analyze the&#xD;
      predictive value of pretransplant levels in myeloma cells of X-box binding protein 1 (XBP1),&#xD;
      inositol-requiring enzyme 1 (IRE1), unspliced XBP1 (XBP1u), sliced XBP1 (XPB1s), XBP1u/XPBs&#xD;
      ratio and v-myc myelocytomatosis viral oncogene homolog (avian) (Myc), by analyzing their&#xD;
      correlation with CR, VGPR+CR and response rate (RR).&#xD;
&#xD;
      VIII. To study the prognostic effect of pretransplant levels in myeloma cells of XBP1, IRE1,&#xD;
      XBP1u, XPB1s, XBP1u/XPBs ratio and Myc, by analyzing their correlation with PFS and OS.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive panobinostat orally (PO) once daily (QD) on days -9 to -2, gemcitabine&#xD;
      hydrochloride intravenously (IV) over 4 hours on days -8 and -3, busulfan IV over 3 hours on&#xD;
      days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo&#xD;
      autologous peripheral blood stem cell transplant on day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1 month, 100 days, 6 months,&#xD;
      1 year, and then every 3-6 months for at least 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2015</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>Estimated by the Kaplan-Meier method. Comparison of time to event endpoints by subgroups will be made using the log-rank test. Cox proportional hazards regression will be employed for univariate and multivariate analysis on time-to-event outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate</measure>
    <time_frame>By day 100</time_frame>
    <description>Assessed using the International Myeloma Working Group (IMWG) uniform response criteria. Reported along with corresponding 95% confidence intervals. Logistic regression will be used to model the association between response rates and prognostic factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated by the Kaplan-Meier method. Comparison of time to event endpoints by subgroups will be made using the log-rank test. Cox proportional hazards regression will be employed for univariate and multivariate analysis on time-to-event outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) + very good partial response (VGPR) rate</measure>
    <time_frame>By day 100</time_frame>
    <description>Assessed using the International Myeloma Working Group (IMWG) uniform response criteria. Reported along with corresponding 95% confidence intervals. Logistic regression will be used to model the association between response rates and prognostic factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>By day 100</time_frame>
    <description>Assessed using the International Myeloma Working Group (IMWG) uniform response criteria. Reported along with corresponding 95% confidence intervals. Logistic regression will be used to model the association between response rates and prognostic factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease post-transplant</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Minimal residual disease post-transplant will be measured by multiparametric flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 or greater side effects</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Assessed according to Common Terminology Criteria for Adverse Events version 4.0. The treatment-related morality rate will be computed and presented with 95% confidence interval. Adverse events will be tabulated for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio, and Myc</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Correlation with PFS and OS of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio and Myc will be analyzed using the log-rank test. The correlation with CR, VGPR+CR and RR of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio, and Myc will be analyzed using Fisher's F test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic effect of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio, and Myc</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Correlation with PFS and OS of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio and Myc will be analyzed using the log-rank test. The correlation with CR, VGPR+CR and RR of pretransplant levels in myeloma cells of XBP1, IRE1, XBP1u, XPB1s, XBP1u/XPBs ratio, and Myc will be analyzed using Fisher's F test.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Plasma Cell Leukemia</condition>
  <condition>Plasmacytoma</condition>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <condition>Refractory Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (panobinostat, Gem/Bu/Mel, ASCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive panobinostat PO QD on days -9 to -2, gemcitabine hydrochloride IV over 4 hours on days -8 and -3, busulfan IV over 3 hours on days -8 to -5, and melphalan IV over 30 minutes on days -3 and -2. Patients then undergo autologous peripheral blood stem cell transplant on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (panobinostat, Gem/Bu/Mel, ASCT)</arm_group_label>
    <other_name>Autologous Hematopoietic Cell Transplantation</other_name>
    <other_name>autologous stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (panobinostat, Gem/Bu/Mel, ASCT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (panobinostat, Gem/Bu/Mel, ASCT)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (panobinostat, Gem/Bu/Mel, ASCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (panobinostat, Gem/Bu/Mel, ASCT)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine nitrogen mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (panobinostat, Gem/Bu/Mel, ASCT)</arm_group_label>
    <other_name>Faridak</other_name>
    <other_name>Farydak</other_name>
    <other_name>LBH589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (panobinostat, Gem/Bu/Mel, ASCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (panobinostat, Gem/Bu/Mel, ASCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Refractory or relapsed myeloma, defined as one or more of the following:&#xD;
&#xD;
               -  Treated with first-line therapy including at least 2 cycles of lenalidomide,&#xD;
                  bortezomib or thalidomide, and one or more of the following:&#xD;
&#xD;
                    -  Less than partial response (PR) to first-line therapy&#xD;
&#xD;
                    -  Relapse after first (1st) line therapy&#xD;
&#xD;
               -  High-risk cytogenetics, defined by deletion (del)(13q) by conventional&#xD;
                  cytogenetics, or by del(17p), t(4;14), t(14;16), t(14;20) or 1q+ by fluorescence&#xD;
                  in situ hybridization (FISH)&#xD;
&#xD;
               -  Relapse after a prior autologous stem cell transplant (ASCT)&#xD;
&#xD;
               -  Plasma cell leukemia&#xD;
&#xD;
               -  Soft tissue plasmacytoma&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.8 mg/dL and/or estimated serum creatinine clearance &gt;= 50 ml/min&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) and/or serum glutamate pyruvate&#xD;
             transaminase (SGPT) =&lt; 3 x upper limit of normal&#xD;
&#xD;
          -  Serum bilirubin =&lt; 2 x upper limit of normal, unless proven to be due to disease&#xD;
             involvement&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 2 x upper limit of normal, unless proven to be due to disease&#xD;
             involvement&#xD;
&#xD;
          -  Adequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced&#xD;
             vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) &gt;=&#xD;
             50% of expected corrected for hemoglobin and/or volume&#xD;
&#xD;
          -  Adequate cardiac function with left ventricular ejection fraction &gt;= 40%&#xD;
&#xD;
          -  No uncontrolled arrhythmias or symptomatic cardiac disease&#xD;
&#xD;
          -  Clinically euthyroid; note: patients are permitted to receive thyroid hormone&#xD;
             supplements to treat underlying hypothyroidism&#xD;
&#xD;
          -  Zubrod performance status &lt; 2&#xD;
&#xD;
          -  Negative beta-human chorionic gonadotropin (HCG) test in a woman of child-bearing&#xD;
             potential, defined as not post-menopausal for 12 months or no previous surgical&#xD;
             sterilization&#xD;
&#xD;
          -  Availability of &gt;= 2.5 million cluster of differentiation (CD)34+ cells/kg previously&#xD;
             apheresed&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior whole brain irradiation&#xD;
&#xD;
          -  Having received radiation therapy to head and neck (excluding eyes), and internal&#xD;
             organs of chest, abdomen or pelvis in the month prior to enrollment&#xD;
&#xD;
          -  Active hepatitis B, either active carrier (hepatitis B surface antigen positive [HBsAg&#xD;
             +]) or viremic (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] &gt;= 10,000&#xD;
             copies/mL, or &gt;= 2,000 IU/mL)&#xD;
&#xD;
          -  Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic&#xD;
             hepatitis C or positive hepatitis C serology&#xD;
&#xD;
          -  Active infection requiring parenteral antibiotics&#xD;
&#xD;
          -  Known positivity for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Autologous stem-cell transplant in the previous six months&#xD;
&#xD;
          -  Needing valproic acid for any medical condition during the study or within 5 days&#xD;
             prior to first panobinostat treatment&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of panobinostat&#xD;
&#xD;
          -  Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled&#xD;
             diabetes or active or uncontrolled infection) including abnormal laboratory values,&#xD;
             that could cause unacceptable safety risks or compromise compliance with the protocol&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac diseases, including any&#xD;
             one of the following:&#xD;
&#xD;
               -  History or presence of sustained ventricular tachyarrhythmia; (patients with a&#xD;
                  history of atrial arrhythmia are eligible but should be discussed with Novartis&#xD;
                  prior to enrollment)&#xD;
&#xD;
               -  Any history of ventricular fibrillation or torsade de pointes&#xD;
&#xD;
               -  Bradycardia defined as heart rate (HR) &lt; 50 beats per minute (bpm); patients with&#xD;
                  pacemakers are eligible if HR &gt;= 50 bpm&#xD;
&#xD;
               -  Screening electrocardiogram (ECG) with a corrected QT (QTc) &gt; 470 msec&#xD;
&#xD;
               -  Right bundle branch block + left anterior hemiblock (bifascicular block)&#xD;
&#xD;
               -  Myocardial infarction or unstable angina =&lt; 12 months prior to starting study&#xD;
                  drug&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g., congestive heart failure [CHF]&#xD;
                  New York [NY] Heart Association class III or IV , uncontrolled hypertension,&#xD;
                  history of labile hypertension, or history of poor compliance with an&#xD;
                  antihypertensive regimen)&#xD;
&#xD;
          -  Have undergone major surgery =&lt; 4 weeks prior to starting study drug or who have not&#xD;
             recovered from side effects of such therapy&#xD;
&#xD;
          -  Prior malignancy with in the last 5 years (except for basal or squamous cell&#xD;
             carcinoma, or in situ cancer of the cervix)&#xD;
&#xD;
          -  Any significant history of non-compliance to medical regimens or unwilling or unable&#xD;
             to comply with the instructions given to him/her by the study staff&#xD;
&#xD;
          -  Received targeted agents within 2 weeks or within 5 half-lives of the agent and active&#xD;
             metabolites (whichever is longer) and who have not recovered from side effects of&#xD;
             those therapies&#xD;
&#xD;
          -  Having received immunotherapy or chemotherapy within 2 weeks; or radiation therapy to&#xD;
             &gt; 30% of marrow-bearing bone within =&lt; 2 weeks prior to starting study treatment; or&#xD;
             who have not yet recovered from side effects of such therapies&#xD;
&#xD;
          -  Grade &gt;= 3 nonhematological toxicity from prior therapy that has not resolved to =&lt;&#xD;
             grade 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yago L Nieto</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yago Nieto</last_name>
    <phone>713-792-8750</phone>
    <email>ynieto@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yago L. Nieto</last_name>
      <phone>713-792-8750</phone>
      <email>ynieto@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Yago L. Nieto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Leukemia, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

